



COVID-19

Science Brief: Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19

Updated May 12, 2021

[Print](#)

For more information, please see: [Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers and the People with Certain Medical Conditions](#) webpage, which is intended for the general public.

Summary of Recent Changes

Updates as of May 13, 2021

Updates to the list of underlying medical conditions that put adults of any age at high risk for severe illness from the virus that causes COVID-19 were based on evidence from published reports, scientific articles in press, unreviewed pre-prints, and internal data. Updates to the following conditions were completed based on evidence from the date range below:

- Pregnancy related references were added in May 2021.
- Substance use disorders were based on evidence published between December 1, 2019, and January 2021.
- Asthma, blood disorders, cancer, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cystic fibrosis, diabetes, Down syndrome, heart disease, hypertension, immunosuppressant medications, use of corticosteroids or other immunosuppressive medications, solid organ or blood stem cell transplantation, neurological conditions, and obesity were based on evidence published between December 1, 2019, and December 2020.
- Smoking was based on evidence published between December 1, 2019, and July 20, 2020.
- All other conditions were based on evidence published between December 1, 2019, and October 16, 2020.

In keeping with an ever-growing volume of literature, references are now categorized by study type. With these categories, we can be more specific about the type of study used as supporting evidence. By presenting the references in these categories, clinicians can better evaluate the quality of the data to determine risk.

No conditions were removed from the previous underlying medical conditions list.

Context

There is much to learn about the newly emerged COVID-19. Based on available literature and data from CDC-led investigations, we continue to learn more about COVID-19 and associated underlying medical conditions that put adults at increased risk of severe illness. Severe illness from COVID-19 is defined here as hospitalization, admission to the intensive care unit (ICU), intubation or mechanical ventilation, or death. Evidence used to inform this list was determined by CDC reviewers based on available evidence about COVID-19 **at time of review**.

Overview

Conditions on this list have been shown to be associated with severe illness from COVID-19. Updates to the conditions below were based on published reports, scientific articles in press, unreviewed pre-prints, and data from CDC-led investigations. Conditions were categorized by the type of study design:

- **Supported by meta-analysis/systematic review:** Defined as having a significant association in at least one meta-analysis or systematic review.
- **Supported by mostly cohort, case-control, or cross sectional studies:** Defined as having an association in cohort, case-control or cross sectional studies; may include systematic review or meta-analysis that represents one condition in a larger group of conditions (for example, kidney transplant under the category of solid organ or blood stem cell transplantation).
- **Supported by mostly case series, case reports or, if other study design, the sample size is small (and no systematic review or meta-analysis were available to review):** Defined as having an association in one or more case series studies. If there are cohort or case-control studies, sample sizes were small. Conditions included may be rare.
- **Supported by mixed evidence:** Defined as having an association in at least one meta-analysis or systematic review and additional studies or reviews that reached different conclusions about risk associated with a condition.

In keeping with an ever-growing volume of literature, references are now categorized by study type. With these categories, we can be more specific about the type of study used as supporting evidence. By presenting the references in these categories, clinicians can better evaluate the quality of the data to determine risk.

To learn more about the study designs used to determine the risk of severe COVID-19 outcomes in these research studies, providers can review the following:

[Principles of Epidemiology | Lesson 1 – Overview \(cdc.gov\)](#)

[Principles of Epidemiology | Lesson 1 – Section 7 \(cdc.gov\)](#)

[Rating Evidence in Medical Literature | Journal of Ethics | American Medical Association \(ama-assn.org\)](#) 

This list might change and, upon review as the science evolves, CDC might update it.

Based on available evidence, conditions could move between evidence categories. Aside from substance use disorders and Down syndrome, last reviewed in January 2021 and December 2020, respectively, no additional condition has been added to this list. If strong and consistent evidence demonstrated no association with severe outcomes, it may be removed from the list. No conditions were removed from the previous underlying medical conditions list.

Table of Evidence

Evidence used to inform the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. In alphabetic order by section.

Tier	Condition	Evidence of Impact on COVID-19 Severity [Reference number]
Supported by meta-analysis/systematic review	Cancer	Systematic Review [1, 2] Cohort Study [3-5] Case Series [6-8] Case Control Study [9]
	Cerebrovascular disease	Meta-Analysis [10-13] Synthesis of Evidence [14] Cohort Study [15-17]
	Chronic kidney disease	Meta-Analysis [13, 18] Cohort Studies [16, 19-40], {41}* Case Series [42-44]
	COPD	Meta-Analysis [45-47] Systematic Review [48, 49]
	Diabetes mellitus, type 1	Meta-Analysis [50] Case Series [43] Cohort Study [15, 51-56]
	Diabetes mellitus, type 2	Meta-Analysis [57] Systematic Review {58}* Gestational Diabetes Systematic Review {59}* Case Series [43] Longitudinal Study [60] Cohort Study [50, 54, 60-65]
	Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies)	Meta-Analysis [66-68] Cohort Study [15, 16]
	Smoking, current and former	Meta-Analysis [45, 67, 69-76]
	Obesity	Systematic Review {58}* Cohort [24, 80-88], {41, 89-92}* Meta-Analysis [77-79]
	Pregnancy and Recent Pregnancy	Systematic Review [58, 93] Case Control [94, 95] Case Series [96-98] Cohort Study [99-102]
Supported by mostly cohort, case-control, or cross-sectional studies (if there is a systematic review or meta-analysis available, it represents one condition in a larger category of conditions)	Children with certain underlying conditions	Systematic Review [103, 104] Cross-Sectional Study [105-107] Cohort Study [108-116] Case Series [117, 118]
	Down syndrome	Cohort Study [119, 120]
	HIV	Cohort Study [32, 121-123]

		Case Series [124-126]
	Neurologic conditions	Review [127] Cross-Sectional Study [105] Cohort Study [16, 108]
	Overweight	Cohort Study [83] Case Series [88]
	Other lung disease (including interstitial lung disease, pulmonary fibrosis, pulmonary hypertension)	Cohort [128-130], {92}*
	Sickle cell disease	Cohort [117, 118, 131, 132] Case Series [117, 132-147]
	Solid organ or blood stem cell transplantation	Meta-Analysis [86] Case Series [148-159] Cohort [160]
	Substance use disorders	Case-Control Study [161-163] Cohort Study [164, 165]
	Use of corticosteroids or other immunosuppressive medications	Cohort Study [166] Cross Sectional [167] Case Series [168-170]
Supported by mostly case series, case reports or, if other study design, the sample size is small (and no systematic review or meta-analysis available were reviewed)	Cystic fibrosis	Case Series [171-173] Cohort [174]
	Thalassemia	Case Series [175-178] Cross Sectional [179]
Supported by mixed evidence	Asthma	Meta-Analysis [180-182] Review [183] Case Series [184] Cohort Study [16, 40, 185-190]
	Hypertension	Meta-Analysis [67, 191-194] Systematic Review [195], {58}* Cohort Study [15, 16, 19, 187, 196-202] Case Series [203]
	Liver disease	Meta-Analysis [204-208] Cohort [19, 28, 42, 209-223] Case-Control [224-229] Cross sectional [230] Case Series [231-233]
	Immune deficiencies	Meta-Analysis [234] Cohort [235-237] Case Series [148, 149, 157, 238-241]

Footnote: { }* indicates pregnancy-related reference.

Literature cited above was provided and reviewed by CDC reviewers, categorized, and added to the table (if not already on the previous underlying medical conditions list [originally released in March 2020]). The following categories were used:

Supported by meta-analysis/systematic review: Defined as having a significant association in at least one meta-analysis or systematic review.

Supported by mostly cohort, case-control, or cross sectional studies (if there is a systematic review or meta-analysis available, it represents one condition in a larger group of conditions): Defined as having an association in cohort, case-control, or cross sectional studies; may include systematic review or meta-analysis that represents one condition in a larger group of conditions (for example, kidney transplant under the category of solid organ or blood stem cell transplantation).

Supported by mostly case series, case reports or, if other study design, the sample size is small (and no systematic review or meta-analysis were available to review): Defined as having an association in one or more case series studies. If there are cohort or case-control studies, sample sizes were small. Conditions included may be rare.

Supported by mixed evidence: Defined as having an association in at least one meta-analysis or systematic review and additional multiple studies or reviews that reached different conclusions about risk associated with a condition.

References:

1. Saini, K.S., et al., Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. *Eur J Cancer*, 2020. 139: p. 43-50. doi: 10.1016/j.ejca.2020.08.011 [↗](#)
2. Zhou, Y., et al., Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. *Int J Infect Dis*, 2020. 99: p. 47-56. doi: 10.1016/j.ijid.2020.07.029 [↗](#)
3. Liang, W., et al., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*, 2020. 21(3): p. 335-337. doi: 10.1016/S1470-2045(20)30096-6 [↗](#)
4. Nepogodiev, D., et al., Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. *The Lancet*, 2020. 396(10243): p. 27-38. doi: 10.1016/S0140-6736(20)31182-X [↗](#)
5. Lee, L.Y., et al., COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet*, 2020. 395(10241): p. 1919-1926. doi: 10.1016/S0140-6736(20)31173-9 [↗](#)
6. Robilotti, E.V., et al., Determinants of COVID-19 disease severity in patients with cancer. *Nat Med*, 2020. 26(8): p. 1218-1223. doi: 10.1038/s41591-020-0979-0 [↗](#)
7. Zhang, H., et al., Outcomes of novel coronavirus disease 2019 (COVID-19) infection in

- 107 patients with cancer from Wuhan, China. *Cancer*, 2020. 126(17): p. 4023-4031. doi: 10.1002/cncr.33042 [↗](#)
8. Kuderer, N.M., et al., Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*, 2020. 395(10241): p. 1907-1918. doi: 10.1016/S0140-6736(20)31187-9 [↗](#)
 9. Wang, Q., N.A. Berger, and R. Xu, Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. *JAMA Oncol*, 2020. doi: 10.1001/jamaoncol.2020.6178 [↗](#)
 10. Pranata, R., et al., Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. *J Stroke Cerebrovasc Dis*, 2020. 29(8): p. 104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949 [↗](#)
 11. Wang, B., et al., Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging (Albany NY)*, 2020. 12(7): p. 6049-6057. doi: 10.18632/aging.103000 [↗](#)
 12. Ssentongo, P., et al., Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. *PLoS One*, 2020. 15(8): p. e0238215. doi: 10.1371/journal.pone.0238215 [↗](#)
 13. Khan, M.M.A., et al., Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis. *J Glob Health*, 2020. 10(2): p. 020503. doi: 10.7189/jogh.10.020503 [↗](#)
 14. Martins-Filho, P.R., C.S.S. Tavares, and V.S. Santos, Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. *Eur J Intern Med*, 2020. 76: p. 97-99. doi: 10.1016/j.ejim.2020.04.043 [↗](#)
 15. Chen, R., et al., Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest*, 2020. 158(1): p. 97-105. doi: 10.1016/j.chest.2020.04.010 [↗](#)
 16. Williamson, E.J., et al., Factors associated with COVID-19-related death using OpenSAFELY. *Nature*, 2020. 584(7821): p. 430-436. doi: 10.1038/s41586-020-2521-4 [↗](#)
 17. Wang, L., et al., Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *J Infect*, 2020. 80(6): p. 639-645. doi: 10.1016/j.jinf.2020.03.019 [↗](#)
 18. Fajgenbaum, D.C., et al., Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. *Infect Dis Ther*, 2020. 9(3): p. 435-449. doi: 10.1007/s40121-020-00303-8 [↗](#)
 19. Gottlieb, M., et al., Clinical Course and Factors Associated With Hospitalization and Critical Illness Among COVID-19 Patients in Chicago, Illinois. *Acad Emerg Med*, 2020. 27(10): p. 963-973. doi: 10.1111/acem.14104 [↗](#)
 20. Fernandes, D.M., et al., Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth. *J Pediatr*, 2020. doi: 10.1016/j.jpeds.2020.11.016 [↗](#)
 21. Hernández-Galdamez, D.R., et al., Increased Risk of Hospitalization and Death in

- Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico. *Arch Med Res*, 2020. 51(7): p. 683-689. doi: 10.1016/j.arcmed.2020.07.003 [↗](#)
22. Menezes Soares, R.D.C., L.R. Mattos, and L.M. Raposo, Risk Factors for Hospitalization and Mortality due to COVID-19 in Espirito Santo State, Brazil. *American Journal of Tropical Medicine and Hygiene*, 2020. 103(3): p. 1184-1190. doi: 10.4269/ajtmh.20-0483 [↗](#)
 23. Oetjens, M.T., et al., Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients. *PloS one*, 2020. 15(11): p. e0242182. doi: 10.1371/journal.pone.0242182 [↗](#)
 24. Petrilli, C.M., et al., Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *Bmj*, 2020. 369: p. m1966. doi: 10.1136/bmj.m1966 [↗](#)
 25. Reilev, M., et al., Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. *International journal of epidemiology*, 2020. doi: 10.1093/ije/dyaa140 [↗](#)
 26. Suleyman, G., et al., Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. *JAMA Netw Open*, 2020. 3(6): p. e2012270. doi: 10.1001/jamanetworkopen.2020.12270 [↗](#)
 27. Rastad, H., et al., Factors associated with the poor outcomes in diabetic patients with COVID-19. *Journal of Diabetes and Metabolic Disorders*, 2020. doi: 10.1007/s40200-020-00646-6 [↗](#)
 28. Fried, M.W., et al., Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 2020. doi: 10.1093/cid/ciaa1268 [↗](#)
 29. Kolhe, N.V., et al., Acute kidney injury associated with COVID-19: A retrospective cohort study. *PLoS Med*, 2020. 17(10): p. e1003406. doi: 10.1371/journal.pmed.1003406 [↗](#)
 30. Bowe, B., et al., Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. *Clin J Am Soc Nephrol*, 2020. doi: 10.2215/CJN.09610620 [↗](#)
 31. McKeigue, P.M., et al., Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. *PLoS medicine*, 2020. 17(10): p. e1003374. doi: 10.1371/journal.pmed.1003374 [↗](#)
 32. Boule, A., et al., Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. *Clin Infect Dis*, 2020. doi: 10.1093/cid/ciaa1198 [↗](#)
 33. Parra-Bracamonte, G.M., N. Lopez-Villalobos, and F.E. Parra-Bracamonte, Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. *Annals of Epidemiology*, 2020. doi: 10.1016/j.annepidem.2020.08.005 [↗](#)

34. Ng, J.H., et al., Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. *Kidney international*, 2020. doi: 10.1016/j.kint.2020.07.030 [↗](#)
35. Omrani, A.S., et al., The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. *BMC Infectious Diseases*, 2020. 20(1): p. 777. doi: 10.1186/s12879-020-05511-8 [↗](#)
36. Iaccarino, G., et al., Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. *PLoS ONE*, 2020. 15(10 October): p. e0237297. doi: 10.1371/journal.pone.0237297 [↗](#)
37. Gu, T., et al., History of coronary heart disease increased the mortality rate of patients with COVID-19: a nested case-control study. *BMJ Open*, 2020. 10(9): p. e038976. doi: 10.1136/bmjopen-2020-038976 [↗](#)
38. Myers, L.C., et al., Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. *Jama*, 2020. 323(21): p. 2195-2198. doi:10.1001/jama.2020.7202 [↗](#)
39. Hirsch, J.S., et al., Acute kidney injury in patients hospitalized with COVID-19. *Kidney Int*, 2020. 98(1): p. 209-218. doi: 10.1016/j.kint.2020.05.006 [↗](#)
40. Gold, J.A.W., et al., Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 – Georgia, March 2020. *MMWR Morb Mortal Wkly Rep*, 2020. 69(18): p. 545-550. doi: 10.15585/mmwr.mm6918e1
41. Jering, K.S., et al., Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19. *JAMA Intern Med*. doi:10.1001/jamainternmed.2020.9241 [↗](#)
42. Garg, S., et al., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep*, 2020. 69(15): p. 458-464. doi: 10.15585/mmwr.mm6915e3
43. Richardson, S., et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*, 2020. 323(20): p. 2052-2059. doi:10.1001/jama.2020.6775 [↗](#)
44. Lee, J.Y., et al., Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea. *Int J Infect Dis*, 2020. 98: p. 462-466. doi: 10.1016/j.ijid.2020.07.017 [↗](#)
45. Lippi, G. and B.M. Henry, Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). *Respir Med*, 2020. 167: p. 105941. doi: 10.1016/j.rmed.2020.105941 [↗](#)
46. Dorjee, K., et al., Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. *PLoS One*, 2020. 15(12): p. e0243191. doi: 10.1371/journal.pone.0243191 [↗](#)
47. Xiao, W.W., et al., Is chronic obstructive pulmonary disease an independent predictor for adverse outcomes in coronavirus disease 2019 patients? *Eur Rev Med Pharmacol Sci*, 2020. 24(21): p. 11421-11427. doi: 10.26355/eurrev_202011_23635 [↗](#)

48. Izcovich, A., et al., Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. *PLoS One*, 2020. 15(11): p. e0241955. doi: 10.1371/journal.pone.0241955 [↗](#)
49. Rabbani, G., et al., Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: a rapid systematic review and meta-analysis. *Expert Rev Respir Med*, 2020. doi: 10.1080/17476348.2021.1866547 [↗](#)
50. Fadini, G.P., et al., Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. *Diabetes Res Clin Pract*, 2020. 168: p. 108374. doi: 10.1016/j.diabres.2020.108374 [↗](#)
51. Barron, E., et al., Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol*, 2020. 8(10): p. 813-822. doi: 10.1016/S2213-8587(20)30272-2 [↗](#)
52. Gregory, J.M., et al., COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. *Diabetes Care*, 2020. doi: 10.2337/dc20-2260 [↗](#)
53. Duarte-Salles, T., et al., Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study. *medRxiv*, 2020. doi: 10.1101/2020.10.29.20222083 [↗](#)
54. Bode, B., et al., Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. *J Diabetes Sci Technol*, 2020. 14(4): p. 813-821. doi: 10.1177/1932296820924469 [↗](#)
55. Vangoitsenhoven, R., et al., No Evidence of Increased Hospitalization Rate for COVID-19 in Community-Dwelling Patients With Type 1 Diabetes. 2020. 43(10): p. e118-e119. doi: 10.2337/dc20-1246 [↗](#)
56. Cardona-Hernandez, R., et al., Children and youth with diabetes are not at increased risk for hospitalization due to COVID-19. *Pediatr Diabetes*, 2020. doi: 10.1111/pedi.13158 [↗](#)
57. Fadini, G.P., et al., Prevalence and impact of diabetes among people infected with SARS-CoV-2. *J Endocrinol Invest*, 2020. 43(6): p. 867-869. doi: 10.1007/s40618-020-01236-2 [↗](#)
58. Allotey, J., et al., Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ*, 2020. 370: p. m3320. doi: 10.1136/bmj.m3320 [↗](#)
59. Wei, S.Q., et al. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. *CMAJ*, 2021. doi: 10.1503/cmaj.202604 [↗](#)
60. Zhu, L., et al., Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metabolism*, 2020. 31(6): p. 1068-1077.e3. doi: 10.1016/j.cmet.2020.04.021 [↗](#)
61. Chen, Y., et al., Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. *Diabetes Care*, 2020. 43(7): p. 1399-1407. doi: 10.2337/dc20-0660 [↗](#)

62. Sathish, T., et al., Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. *Diabetes Obes Metab*, 2020. doi: 10.1111/dom.14269 [↗](#)
63. de Almeida-Pititto, B., et al., Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. *Diabetol Metab Syndr*, 2020. 12: p. 75. doi: 10.1186/s13098-020-00586-4 [↗](#)
64. Kow, C.S. and S.S. Hasan, Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. *J Med Virol*, 2020. doi: 10.1002/jmv.26498 [↗](#)
65. Perez-Belmonte, L.M., et al., Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. *BMC Med*, 2020. 18(1): p. 359. doi: 10.1186/s12916-020-01832-2 [↗](#)
66. Del Sole, F., et al., Features of severe COVID-19: A systematic review and meta-analysis. *Eur J Clin Invest*, 2020. 50(10): p. e13378. doi: 10.1111/eci.13378 [↗](#)
67. Zheng, Z., et al., Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect*, 2020. 81(2): p. e16-e25. doi: 10.1016/j.jinf.2020.04.021 [↗](#)
68. Yang, J., et al., Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis*, 2020. 94: p. 91-95. doi: 10.1016/j.ijid.2020.03.017 [↗](#)
69. Patanavanich, R. and S.A. Glantz, Smoking Is Associated With COVID-19 Progression: A Meta-analysis. *Nicotine Tob Res*, 2020. 22(9): p. 1653-1656. doi: 10.1093/ntr/ntaa082 [↗](#)
70. Guo, F.R., Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): An update of a meta-analysis. *Tob Induc Dis*, 2020. 18: p. 37. doi: 10.18332/tid/121915 [↗](#)
71. Zhao, Q., et al., The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. *J Med Virol*, 2020. 92(10): p. 1915-1921. doi: 10.1002/jmv.25889 [↗](#)
72. Lippi, G. and B.M. Henry, Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). *Eur J Intern Med*, 2020. 75: p. 107-108. doi: 10.1016/j.ejim.2020.03.014 [↗](#)
73. Alqahtani, J.S., et al., Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. *PLoS One*, 2020. 15(5): p. e0233147. doi: 10.1371/journal.pone.0233147 [↗](#)
74. Li, J., et al., Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. *Am J Infect Control*, 2020. doi: 10.1016/j.ajic.2020.06.008 [↗](#)
75. Farsalinos, K., et al., Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. *Ther Adv Chronic Dis*, 2020. 11: p. 2040622320935765. doi: 10.1177/2040622320935765 [↗](#)
76. Sanchez-Ramirez, D.C. and D. Mackey, Underlying respiratory diseases, specifically

- COPD, and smoking are associated with severe COVID-19 outcomes: A systematic review and meta-analysis. *Respir Med*, 2020. 171: p. 106096. doi: 10.1016/j.rmed.2020.106096 [↗](#)
77. Yang, J., J. Hu, and C. Zhu, Obesity aggravates COVID-19: A systematic review and meta-analysis. *J Med Virol*, 2020. doi: 10.1002/jmv.26237 [↗](#)
78. Tsankov, B.K., et al., Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis. *Int J Infect Dis*, 2020. 103: p. 246-256. doi: 10.1016/j.ijid.2020.11.163 [↗](#)
79. Foldi, M., et al., Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis. *Obes Rev*, 2020. 21(10): p. e13095. doi: 10.1111/obr.13095 [↗](#)
80. Lighter, J., et al., Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. *Clin Infect Dis*, 2020. 71(15): p. 896-897. doi: 10.1093/cid/ciaa415 [↗](#)
81. Tartof, S.Y., et al., Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. *Ann Intern Med*, 2020. 173(10): p. 773-781. doi: 10.7326/M20-3742 [↗](#)
82. Hur, K., et al., Factors Associated With Intubation and Prolonged Intubation in Hospitalized Patients With COVID-19. *Otolaryngol Head Neck Surg*, 2020. 163(1): p. 170-178. doi: 10.1177/0194599820929640 [↗](#)
83. Hamer, M., et al., Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. *Proc Natl Acad Sci U S A*, 2020. 117(35): p. 21011-21013. doi: 10.1073/pnas.2011086117 [↗](#)
84. Simonnet, A., et al., High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity (Silver Spring)*, 2020. 28(7): p. 1195-1199. doi: 10.1002/oby.22831 [↗](#)
85. Palaiodimos, L., et al., Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. *Metabolism*, 2020. 108: p. 154262. doi: 10.1016/j.metabol.2020.154262 [↗](#)
86. Aziz, F., et al., Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019. *Transplant Proc*, 2020. 52(9): p. 2659-2662. doi: 10.1016/j.transproceed.2020.07.002 [↗](#)
87. Ko, J.Y., et al., Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. *Clinical Infectious Diseases*, 2020. doi: 10.1093/cid/ciaa1419 [↗](#)
88. Nakeshbandi, M., et al., The impact of obesity on COVID-19 complications: a retrospective cohort study. *Int J Obes (Lond)*, 2020. 44(9): p. 1832-1837. doi: 10.1038/s41366-020-0648-x [↗](#)
89. DiMartino, D.D., et al., Assessing risk factors for severe forms of COVID-19 in a pregnant population: A clinical series from Lombardy, Italy. *Int. J. Gynecol. Obstet*,

2021. 152(2): p. 275–277. doi: 10.1002/ijgo.13435 [↗](#)
90. Khoury, R., et al., Characteristics and Outcomes of 241 Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection at Five New York City Medical Centers. *Obstet Gynecol*, 2020. 136(2): p. 273–282. doi: 10.1097/AOG.0000000000004025 [↗](#)
 91. Metz, T.D. et al., Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol*, 2021. 137(4): p. 571–580. doi: 10.1097/AOG.0000000000004339 [↗](#)
 92. Galang, R.R., et al., Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection – Surveillance for Emerging Threats to Mothers and Babies Network, 20 state, local, and territorial health departments, March 29, 2020 - January 8, 2021. Preprint. medRxiv, 2021. doi: 10.1101/2021.02.27.21252169 [↗](#)
 93. Yang, Z., et al., Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review. *J Matern Fetal Neonatal Med*, 2020: p. 1-4. doi: 10.1080/14767058.2020.1759541 [↗](#)
 94. Collin, J., et al., Public Health Agency of Sweden’s Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. *Acta Obstet Gynecol Scand*, 2020. 99(7): p. 819-822. doi: 10.1111/aogs.13901 [↗](#)
 95. Li, N., et al., Maternal and Neonatal Outcomes of Pregnant Women With Coronavirus Disease 2019 (COVID-19) Pneumonia: A Case-Control Study. *Clin Infect Dis*, 2020. 71(16): p. 2035-2041. doi: 10.1093/cid/ciaa352 [↗](#)
 96. Chen, L., et al., Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. *N Engl J Med*, 2020. 382(25): p. e100. doi: 10.1056/NEJMc2009226 [↗](#)
 97. Breslin, N., et al., Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol MFM*, 2020. 2(2): p. 100118. doi: doi: 10.1016/j.ajogmf.2020.100118 [↗](#)
 98. Lokken, E.M., et al., Clinical Characteristics of 46 Pregnant Women with a SARS-CoV-2 Infection in Washington State. *American Journal of Obstetrics and Gynecology*, 2020. 223 (6): 911 p.e1–911.e14. doi: 10.1016/j.ajog.2020.05.031 [↗](#)
 99. Pierce-Williams, R.A.M., et al., Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. *Am J Obstet Gynecol MFM*, 2020. 2(3). doi: 10.1016/j.ajogmf.2020.100134 [↗](#)
 100. Savasi, V.M., et al., Clinical Findings and Disease Severity in Hospitalized Pregnant Women With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol*, 2020. 136(2): p. 252-258. doi: 10.1097/AOG.0000000000003979 [↗](#)
 101. Ellington, S., et al., Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status – United States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep*, 2020. 69(25): p. 769-775. doi: 10.15585/mmwr.mm6925a1 [↗](#)
 102. Zambrano, L.D., et al., Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy

- Status – United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep*, 2020. 69(44): p. 1641–1647. doi: 10.15585/mmwr.mm6944e3 [↗](#)
103. Alsaied, T., et al., Coronavirus Disease 2019 (COVID-19) Pandemic Implications in Pediatric and Adult Congenital Heart Disease. *J Am Heart Assoc*, 2020. 9(12). doi: 10.1161/JAHA.120.017224 [↗](#)
104. Sanna, G., et al., Children’s heart and COVID-19: Up-to-date evidence in the form of a systematic review. *Eur J Pediatr*, 2020. 179(7): p. 1079–1087. doi: 10.1007/s00431-020-03699-0 [↗](#)
105. Shekerdemian, L.S., et al., Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatr*, 2020. 174(9): p. 868–873. doi:10.1001/jamapediatrics.2020.1948 [↗](#)
106. Sabatino, J., et al., COVID-19 and Congenital Heart Disease: Results from a Nationwide Survey. *J Clin Med*, 2020. 9(6). p. 1–8. doi: 10.3390/jcm9061774 [↗](#)
107. Bellino, S., et al., COVID-19 Disease Severity Risk Factors for Pediatric Patients in Italy. *Pediatrics*, 2020. 146(4). doi: 10.1542/peds.2020-009399 [↗](#)
108. Parri, N., et al., Children with Covid-19 in Pediatric Emergency Departments in Italy. *N Engl J Med*, 2020. 383(2): p. 187–190. doi: 10.1056/NEJMc2007617 [↗](#)
109. DeBiasi, R.L., et al., Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. *J Pediatr*, 2020. 223: p. 199–203.e1. doi: 10.1016/j.jpeds.2020.05.007 [↗](#)
110. Chao, J.Y., et al., Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. *J Pediatr*, 2020. 223: p. 14–19.e2. doi: 10.1016/j.jpeds.2020.05.006 [↗](#)
111. Kim, D.W., et al., The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data. *Journal of Korean medical science*, 2020. 35(26). doi: 10.3346/jkms.2020.35.e243 [↗](#)
112. Gonzalez-Dambrauskas, S., et al., Pediatric Critical Care and COVID-19. *Pediatrics*, 2020. 146(3). doi:10.1542/peds.2020-1766 [↗](#)
113. Gotzinger, F., et al., COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health*, 2020. 4(9): p. 653–661. doi: 10.1016/S2352-4642(20)30177-2 [↗](#)
114. Zachariah, P., et al., Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. *JAMA Pediatr*, 2020. 174(10). doi:10.1001/jamapediatrics.2020.2430 [↗](#)
115. Verma, S., et al., Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan Area. *Hosp Pediatr*, 2021. 11(1): p. 71–78. doi: 10.1542/hpeds.2020-001917 [↗](#)
116. Leon-Abarca, J.A., Obesity and immunodeficiencies are the main pre-existing conditions associated with mild to moderate COVID-19 in children. *Pediatr Obes*, 2020. 15(12). doi: 10.1111/ijpo.12713 [↗](#)

117. Oualha, M., et al., Severe and fatal forms of COVID-19 in children. *Arch Pediatr*, 2020. 27(5): p. 235-238. doi: 10.1016/j.arcped.2020.05.010 [↗](#)
118. Heilbronner, C., et al., Patients with sickle cell disease and suspected COVID-19 in a paediatric intensive care unit. *Br J Haematol*, 2020. 190(1): p. e21-e24. doi: 10.1111/bjh.16802 [↗](#)
119. Huls, A., et al., An international survey on the impact of COVID-19 in individuals with Down syndrome. *medRxiv*, 2020. doi:10.1101/2020.11.03.20225359 [↗](#)
120. Clift, A.K., et al., COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study Of 8 Million Adults. *Ann Intern Med*, 2020. doi: 10.7326/M20-4986 [↗](#)
121. Bhaskaran, K., et al., HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. *Lancet HIV*, 2020. doi: 10.1016/S2352-3018(20)30305-2 [↗](#)
122. Hadi, Y.B., et al., Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study. *Aids*, 2020. 34(13): p. F3-f8. doi: 10.1097/QAD.0000000000002666 [↗](#)
123. Miyashita, H. and T. Kuno, Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV infection in New York City. *HIV Med*, 2021. 22(1): p. e1-e2. doi: 10.1111/hiv.12920 [↗](#)
124. Härter, G., et al., COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. *Infection*, 2020. 48(5): p. 681-686. doi: 10.1007/s15010-020-01438-z [↗](#)
125. Altuntas Aydin, O., H. Kumbasar Karaosmanoglu, and K. Kart Yasar, HIV/SARS-CoV-2 coinfecting patients in Istanbul, Turkey. *J Med Virol*, 2020. 92(11): p. 2288-2290. doi: 10.1002/jmv.25955 [↗](#)
126. Ho, H.E., et al., Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. *J Infect Dis*, 2020. doi: 10.1093/infdis/jiaa380 [↗](#)
127. Herman, C., K. Mayer, and A. Sarwal, Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. *Neurology*, 2020. 95(2): p. 77-84. doi: 10.1212/WNL.00000000000009673 [↗](#)
128. Drake, T.M., et al., Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. *American journal of respiratory and critical care medicine*, 2020. 202(12): p. 1656-1665. doi: 10.1164/rccm.202007-2794OC [↗](#)
129. Riou, M., et al., Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study. *Respiratory Medical Research*, 2020. 79. doi: 10.1016/j.resmer.2020.100801 [↗](#)
130. Sahu, K.K., et al., COVID-19 and restrictive lung disease: A deadly combo to trip off the fine balance. *Monaldi Archives for Chest Disease*, 2020. 90(2): p. 395-397. doi: 10.4081/monaldi.2020.1346 [↗](#)
131. Arlet, J.B., et al., Prognosis of patients with sickle cell disease and COVID-19: a French experience. *Lancet Haematol*, 2020. 7(9): p. e632-e634. doi: 10.1016/S2352-3026(20)30204-0 [↗](#)

132. Odièvre, M.H., et al., Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome. *Am J Hematol*, 2020. 95(8): p. E192-e194. doi: 10.1002/ajh.25855 [↗](#)
133. McCloskey, K.A., et al., COVID-19 infection and sickle cell disease: a UK centre experience. *Br J Haematol*, 2020. 190(2): p. e57-e58. doi: 10.1111/bjh.16779 [↗](#)
134. Nur, E., et al., Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). *Am J Hematol*, 2020. 95(6): p. 725-726. doi: 10.1002/ajh.25821 [↗](#)
135. Hussain, F.A., et al., COVID-19 infection in patients with sickle cell disease. *Br J Haematol*, 2020. 189(5): p. 851-852. doi: 10.1111/bjh.16734 [↗](#)
136. Panepinto, J.A., et al., Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20-May 21, 2020. *Emerg Infect Dis*, 2020. 26(10): p. 2473-2476. doi: 10.3201/eid2610.202792
137. Al-Hebshi, A., et al., A Saudi family with sickle cell disease presented with acute crises and COVID-19 infection. *Pediatr Blood Cancer*, 2020. 67(9). [↗](#)
138. Allison, D., et al., Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease? *J Clin Apher*, 2020. 35(4): p. 378-381. doi: 10.1002/jca.21809 [↗](#)
139. Appiah-Kubi, A., et al., Varying presentations and favourable outcomes of COVID-19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases. *Br J Haematol*, 2020. 190(4): p. e221-e224. doi: 10.1111/bjh.17013 [↗](#)
140. Azerad, M.A., et al., Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes. *EJHaem*, 2020. 1(1). P. 388-341. doi: 10.1002/jha2.74 [↗](#)
141. Chakravorty, S., et al., COVID-19 in patients with sickle cell disease – a case series from a UK Tertiary Hospital. *Haematologica*, 2020. 105(11). doi: 10.3324/haematol.2020.254250 [↗](#)
142. De Luna, G., et al., Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. *Am J Hematol*, 2020. 95(7): p. 876-878. doi: 10.1002/ajh.25833 [↗](#)
143. Ershler, W.B. and M.E. Holbrook, Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion. *Transfusion*, 2020. 60(12): p. 3066-3067. doi: 10.1111/trf.16068 [↗](#)
144. Jacob, S., A. Dworkin, and E. Romanos-Sirakis, A pediatric patient with sickle cell disease presenting with severe anemia and splenic sequestration in the setting of COVID-19. *Pediatr Blood Cancer*, 2020. 67(12). doi: 10.1002/pbc.28511 [↗](#)
145. Justino, C.C., et al., COVID-19 as a trigger of acute chest syndrome in a pregnant woman with sickle cell anemia. *Hematol Transfus Cell Ther*, 2020. 42(3): p. 212-214. doi: 10.1016/j.htct.2020.06.003 [↗](#)
146. Morrone, K.A., et al., Acute chest syndrome in the setting of SARS-COV-2 infections-A case series at an urban medical center in the Bronx. *Pediatr Blood Cancer*, 2020. 67(11). doi: 10.1002/pbc.28579 [↗](#)
147. Balanchivadze, N., et al., Impact of COVID-19 Infection on 24 Patients with Sickle Cell Disease. One Center Urban Experience, Detroit, MI, USA. *Hemoglobin*, 2020. 44(4): p.

- 284-289. doi: 10.1080/03630269.2020.1797775 [↗](#)
148. Akalin, E., et al., Covid-19 and Kidney Transplantation. *N Engl J Med*, 2020. 382(25): p. 2475-2477. doi: 10.1056/NEJMc2011117 [↗](#)
 149. Ketcham, S.W., et al., Coronavirus Disease-2019 in Heart Transplant Recipients in Southeastern Michigan: A Case Series. *J Card Fail*, 2020. 26(6): p. 457-461. doi: 10.1016/j.cardfail.2020.05.008 [↗](#)
 150. Latif, F., et al., Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. *JAMA Cardiol*, 2020. doi: 10.1001/jamacardio.2020.2159 [↗](#)
 151. Zhu, L., et al., Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. *Am J Transplant*, 2020. 20(7): p. 1859-1863. doi: 10.1111/ajt.15869 [↗](#)
 152. Fernández-Ruiz, M., et al., COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant*, 2020. 20(7): p. 1849-1858. doi: 10.1111/ajt.15929 [↗](#)
 153. Travi, G., et al., Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience. *Am J Transplant*, 2020. 20(9): p. 2628-2629. doi: 10.1111/ajt.16069 [↗](#)
 154. Tschopp, J., et al., First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. *Am J Transplant*, 2020. 20(10): p. 2876-2882. doi: 10.1111/ajt.16062 [↗](#)
 155. Yi, S.G., et al., Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. *Transplantation*, 2020. 104(11): p. 2208-2214. doi: 10.1097/TP.0000000000003339 [↗](#)
 156. Fung, M., et al., Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States. *Am J Transplant*, 2020. 20(11): p. 3225-3233. doi: 10.1111/ajt.16079 [↗](#)
 157. Hoek, R.A.S., et al., COVID-19 in solid organ transplant recipients: a single-center experience. *Transpl Int*, 2020. 33(9): p. 1099-1105. doi: 10.1111/tri.13662 [↗](#)
 158. Iacovoni, A., et al., A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy. *J Heart Lung Transplant*, 2020. 39(10): p. 1081-1088. doi: 10.1016/j.healun.2020.06.016 [↗](#)
 159. Pereira, M.R., et al., COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. *Am J Transplant*, 2020. 20(7): p. 1800-1808. doi: 10.1111/ajt.15941 [↗](#)
 160. Kates, O.S., et al., COVID-19 in solid organ transplant: A multi-center cohort study. *Clin Infect Dis*, 2020. doi: 10.1093/cid/ciaa1097 [↗](#)
 161. Allen, B., et al., Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. *J Public Health (Oxf)*, 2020. doi: 10.1093/pubmed/fdaa241 [↗](#)
 162. Wang, Q.Q., Kaelber, D.C., Xu, R. et al. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. *Mol Psychiatry* 26, 30–39 (2021). doi:10.1038/s41380-020-00880-7 [↗](#)

163. Ji, W., et al., Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study. *J Korean Med Sci*, 2020. 35(25): p. e237. doi: 10.3346/jkms.2020.35.e237 [↗](#)
164. Lee, S.W., et al., Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. *Lancet Psychiatry*, 2020. 7(12): p. 1025-1031. doi: 10.1016/S2215-0366(20)30421-1 [↗](#)
165. Baillargeon, J., et al., The Impact of Substance Use Disorder on COVID-19 Outcomes. *Psychiatr Serv*, 2020: p. appips202000534. doi: 10.1176/appi.ps.202000534 [↗](#)
166. Brenner, E.J., et al., Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. *Gastroenterology*, 2020. 159(2): p. 481-491.e3. doi: 10.1053/j.gastro.2020.05.032 [↗](#)
167. Michelena, X., et al., Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. *Semin Arthritis Rheum*, 2020. 50(4): p. 564-570. doi: 10.1016/j.semarthrit.2020.05.001 [↗](#)
168. Di Giorgio, A., et al., Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy. *J Hepatol*, 2020. 73(3): p. 702-705. doi: 10.1016/j.jhep.2020.05.008 [↗](#)
169. Marlais, M., et al., The severity of COVID-19 in children on immunosuppressive medication. *Lancet Child Adolesc Health*, 2020. 4(7): p. e17-e18. doi: 10.1016/S2352-4642(20)30145-0 [↗](#)
170. Montero-Escribano, P., et al., Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. *Mult Scler Relat Disord*, 2020. 42. doi: 10.1016/j.msard.2020.102185 [↗](#)
171. McClenaghan, E., et al., The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. *J Cyst Fibros*, 2020. 19(6): p. 868-871. doi: 10.1016/j.jcf.2020.10.003 [↗](#)
172. Moeller, A., et al., COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres. *ERJ Open Res*, 2020. 6(4). doi: 10.1183/23120541.00409-2020 [↗](#)
173. Cosgriff, R., et al., A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. *J Cyst Fibros*, 2020. 19(3): p. 355-358. doi: 10.1016/j.jcf.2020.04.012 [↗](#)
174. Bain, R., et al., Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. *J Cyst Fibros*, 2020. doi: 10.1016/j.jcf.2020.11.021 [↗](#)
175. Motta, I., et al., SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experience. *Am J Hematol*, 2020. 95(8): p. E198-e199. doi: 10.1002/ajh.25840 [↗](#)
176. Pinto, V.M., et al., COVID-19 in a Patient with beta-Thalassemia Major and Severe Pulmonary Arterial Hypertension. *Hemoglobin*, 2020. 44(3): p. 218-220. doi: 10.1080/03630269.2020.1779082 [↗](#)
177. Sasi, S., et al., A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D

- Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency. *Am J Case Rep*, 2020. 21. doi: 10.12659/AJCR.925788 [↗](#)
178. Sarbay, H., A. Atay, and B. Malbora, COVID-19 Infection in a Child With Thalassemia Major After Hematopoietic Stem Cell Transplant. *J Pediatr Hematol Oncol*, 2021. 43(1): p. 33-34. doi: 10.1097/MPH.0000000000001895 [↗](#)
179. Karimi, M., et al., Prevalence and mortality in β -thalassaemias due to outbreak of novel coronavirus disease (COVID-19): the nationwide Iranian experience. *Br J Haematol*, 2020. 190(3): p. e137-e140. doi: 10.1111/bjh.16911 [↗](#)
180. Wang, Y., et al., Does Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis. *Int Arch Allergy Immunol*, 2020: p. 1-7. doi: 10.1159/000510953 [↗](#)
181. Liu, S., et al., Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. *The Journal of Allergy & Clinical Immunology in Practice*, 2020. 9(2): p. 693-701. doi: 10.1016/j.jaip.2020.11.054 [↗](#)
182. Sunjaya, A.P., et al., Asthma and risk of infection, hospitalisation, ICU admission and mortality from COVID-19: Systematic review and meta-analysis. *Journal of Asthma*, 2021: p. 1-22. doi: 10.1080/02770903.2021.1888116 [↗](#)
183. Morais-Almeida, M., et al., Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review. *Int Arch Allergy Immunol*, 2020. 181(9): p. 680-688. doi: 10.1159/000509057 [↗](#)
184. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep*, 2020. 69(13): p. 382-386.
185. Broadhurst, R., et al., Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? *Ann Am Thorac Soc*, 2020. 17(12): p. 1645-1648. doi: 10.1513/AnnalsATS.202006-613RL [↗](#)
186. Caminati, M., et al., Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. *Respir Med*, 2020. 176. doi: 10.1016/j.rmed.2020.106261 [↗](#)
187. Javanmardi, F., et al., Prevalence of underlying diseases in died cases of COVID-19: A systematic review and meta-analysis. *PLoS One*, 2020. 15(10). doi: 10.1371/journal.pone.0241265 [↗](#)
188. Schultze, A., et al., Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. *Lancet Respir Med*, 2020. 8(11): p. 1106-1120. doi: 10.1016/S2213-2600(20)30415-X [↗](#)
189. Chao, J.Y., et al., Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. *J Pediatr*, 2020. 223: p. 14-19 e2. doi: 10.1016/j.jpeds.2020.05.006 [↗](#)
190. Mahdavinia, M., et al., Asthma prolongs intubation in COVID-19. *J Allergy Clin Immunol Pract*, 2020. 8(7): p. 2388-2391. doi: 10.1016/j.jaip.2020.05.006 [↗](#)
191. Matsushita, K., et al., The Relationship of COVID-19 Severity with Cardiovascular

- Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. *Glob Heart*, 2020. 15(1): p. 64. doi: 10.5334/gh.814 [↗](#)
192. Wu, T., et al., Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis. *Aging Dis*, 2020. 11(4): p. 874-894. doi: 10.14336/AD.2020.0520 [↗](#)
193. Guo, X., Y. Zhu, and Y. Hong, Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. *Hypertension*, 2020. 76(2): p. e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572 [↗](#)
194. Zhang, J., et al., Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. *Epidemiol Infect*, 2020. 148: p. e106. doi: 10.1017/S095026882000117X [↗](#)
195. Pranata, R., et al., Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. *J Renin Angiotensin Aldosterone Syst*, 2020. 21(2): p. 1470320320926899. doi: 10.1177/1470320320926899 [↗](#)
196. Ioannou, G.N., et al., Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection. *JAMA Network Open*, 2020. 3(9): p. e2022310-e2022310. doi:10.1001/jamanetworkopen.2020.22310 [↗](#)
197. Iaccarino, G., et al., Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. *Hypertension*, 2020. 76(2): p. 366-372. doi: 10.1161/HYPERTENSIONAHA.120.15324 [↗](#)
198. Guan, W.J., et al., Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J*, 2020. 55(5). doi 10.1183/13993003.00547-2020 [↗](#)
199. Kim, L., et al., Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). *Clin Infect Dis*, 2020. doi: 10.1093/cid/ciaa1012 [↗](#)
200. Ran, J., et al., Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. *Hypertens Res*, 2020. 43(11): p. 1267-1276. doi: 10.1038/s41440-020-00541-w [↗](#)
201. Yanover, C., et al., What Factors Increase the Risk of Complications in SARS-CoV-2-Infected Patients? A Cohort Study in a Nationwide Israeli Health Organization. *JMIR Public Health Surveill*, 2020. 6(3): p. e20872. doi: 10.2196/20872 [↗](#)
202. Killerby, M.E., et al., Characteristics Associated with Hospitalization Among Patients with COVID-19 – Metropolitan Atlanta, Georgia, March-April 2020. *MMWR Morb Mortal Wkly Rep*, 2020. 69(25): p. 790-794. doi: 10.15585/mmwr.mm6925e1 [↗](#)
203. Chen, R., et al., Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. *J Clin Hypertens (Greenwich)*, 2020. 22(11): p. 1974-1983. doi: 10.1111/jch.14038 [↗](#)
204. Boettler, T., et al., Impact of COVID-19 on the care of patients with liver disease: EASL-

- ESCMID position paper after 6 months of the pandemic. *JHEP Rep*, 2020. 2(5): p. 100169. doi: 10.1016/j.jhepr.2020.100169 [↗](#)
205. Sharma, A., et al., Liver disease and poor outcomes of COVID-19 hospitalizations-a meta-analysis. *Hepatology*, 2020. 72 (1 SUPPL): p. 283A-284A. [↗](#)
206. Kovalic, A.J., S.K. Satapathy, and P.J. Thuluvath, Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. *Hepatology Int*, 2020. 14(5): p. 612-620. doi: 10.1007/s12072-020-10078-2 [↗](#)
207. Patel, U., et al., Age-Adjusted Risk Factors Associated with Mortality and Mechanical Ventilation Utilization Amongst COVID-19 Hospitalizations-a Systematic Review and Meta-Analysis. *SN Compr Clin Med*, 2020: p. 1-10. doi: 10.1007/s42399-020-00476-w [↗](#)
208. Plasencia-Urizarri, T.M., R. Aguilera-Rodriguez, and L.E. Almaguer-Mederos, Comorbidities and clinical severity of COVID-19: systematic review and meta-analysis. [Spanish]. *Revista Habanera de Ciencias Medicas*, 2020. 19 (no pagination)(e3389). [↗](#)
209. Zhou, W., et al., Prognosis models for severe and critical COVID-19 based on the charlson and elixhauser comorbidity indices. *International Journal of Medical Sciences*, 2020. 17(15): p. 2257-2263. doi: 10.7150/ijms.50007 [↗](#)
210. Veloz, M.G., et al., Influence of pre-existing liver disease in the course of COVID-19. in an area with low incidence of SARSCOV2 infection. *Hepatology*, 2020. 72 (1 SUPPL): p. 281A-282A. [↗](#)
211. Trivedi, H., et al., The impact of hepatic steatosis on COVID-19 related outcomes. *Hepatology*, 2020. 72 (1 SUPPL): p. 303A-304A. [↗](#)
212. Suresh, S., et al., Clinical outcomes in hospitalized COVID-19 patients with chronic liver disease and cirrhosis. *Hepatology*, 2020. 72 (1 SUPPL): p. 263A. <http://dx.doi.org/10.1002/hep.31579> [↗](#)
213. Berenguer, J., et al., Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. *Clin Microbiol Infect*, 2020. 26(11): p. 1525-1536. doi: 10.1016/j.cmi.2020.07.024 [↗](#)
214. Chen, X., et al., Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 and Hepatitis B Virus Co-infection. *Virology*, 2020. doi: 10.1007/s12250-020-00276-5 [↗](#)
215. Davidov-Derevyanko, Y., et al., The liver in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection. *Hepatology*, 2020. 72 (1 SUPPL): p. 304A-305A. doi: 10.1097/meg.0000000000002048 [↗](#)
216. Forlano, R., et al., In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. *Hepatology*, 2020. 72 (1 SUPPL): p. 282A-283A. doi: 10.1371/journal.pone.0240400 [↗](#)
217. Harrison, S.L., et al., Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. *PLoS Med*, 2020. 17(9): p. e1003321. doi: 10.1371/journal.pmed.1003321 [↗](#)
218. Hashemi, N., et al., Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience. *Liver Int*, 2020. 40(10): p. 2515-2521. doi: 10.1111/liv.14583 [↗](#)

219. Huang, R., et al., Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. *Hepatol Commun*, 2020. doi: 10.1002/hep4.1592 [↗](#)
220. Kim, D., et al., Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study. *Clin Gastroenterol Hepatol*, 2020. doi: 10.1016/j.cgh.2020.09.027 [↗](#)
221. Krishnan, A., et al., Clinical characteristics and outcomes of COVID-19 patients with and without pre-existing chronic liver disease. *Hepatology*, 2020. 72 (1 SUPPL): p. 262A. <http://dx.doi.org/10.1002/hep.31579> [↗](#)
222. Mangia, A., et al., Are hcv antibodies positive cirrhotic patients at lower risk of death as compared to cirrhotic of different etiologies when infected by COVID-19? *Hepatology*, 2020. 72 (1 SUPPL): p. 259A. [↗](#)
223. Satapathy, S.K., et al., Acute-on-chronic liver failure related to COVID-19 infection is associated with increased in-hospital mortality. *Hepatology*, 2020. 72 (1 SUPPL): p. 80A-81A. <http://dx.doi.org/10.1002/hep.31578> [↗](#)
224. Singh, S. and A. Khan, Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. *Gastroenterology*, 2020. 159(2): p. 768-771.e3. doi: 10.1053/j.gastro.2020.04.064 [↗](#)
225. Liu, J., et al., Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. *Hepatol Res*, 2020. 50(11): p. 1211-1221. doi: 10.1111/hepr.13553 [↗](#)
226. Mandour, M.O., et al., Characteristics of SARS-COV2 And liver cirrhosis-a single-centre experience in the United Kingdom. *Hepatology*, 2020. 72 (1 SUPPL): p. 261A-262A. [↗](#)
227. Mendizabal, M., et al., Abnormal liver function tests on admission are associated with increased mortality in hospitalized patients with COVID-19: Preliminary results from a large Latin American Cohort. *Hepatology*, 2020. 72 (1 SUPPL): p. 79A-80A. <http://dx.doi.org/10.1002/hep.31578> [↗](#)
228. Shalimar, et al., Poor outcomes in patients with cirrhosis and Corona Virus Disease-19. *Indian J Gastroenterol*, 2020. 39(3): p. 285-291. doi: 10.1007/s12664-020-01074-3 [↗](#)
229. Wu, J., et al., Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study. *J Viral Hepat*, 2021. 28(1): p. 80-88. doi: 10.1111/jvh.13404 [↗](#)
230. An, Y.W., et al., Liver function recovery of COVID-19 patients after discharge, a follow-up study. *Int J Med Sci*, 2021. 18(1): p. 176-186. doi: 10.7150/ijms.50691 [↗](#)
231. Eisa, M., et al., SARS-COV-2 infection in patients with alcohol associated hepatitis: Challenge of treatment options. *Hepatology*, 2020. 72 (1 SUPPL): p. 300A. [↗](#)
232. Moon, A.M., et al., High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. *J Hepatol*, 2020. 73(3): p. 705-708. doi: 10.1016/j.jhep.2020.05.013 [↗](#)
233. Singh, A.K., et al., Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis. *United*

- European Gastroenterology Journal, 2020: p. 2050640620972602. doi: 10.1177/2050640620972602 [↗](#)
234. Gao, Y., et al., Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. *J Infect*, 2020. 81(2): p. e93-e95. doi: 10.1016/j.jinf.2020.05.017 [↗](#)
235. Delavari, S., et al., Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency. *J Clin Immunol*, 2020. doi: 10.1007/s10875-020-00928-x [↗](#)
236. Shields, A.M., et al., COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. *J Allergy Clin Immunol*, 2020. doi: 10.1016/j.jaci.2020.12.620 [↗](#)
237. Danziger-Isakov, L., et al., Impact of COVID-19 in solid organ transplant recipients. *Am J Transplant*, 2020. 14(10): p. 16449. doi: 10.1111/ajt.16449 [↗](#)
238. Soresina, A., et al., Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. *Pediatr Allergy Immunol*, 2020. 31(5): p. 565-569. doi: 10.1111/pai.13263 [↗](#)
239. Meyts, I., et al., Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. *J Allergy Clin Immunol*, 2020. doi: 10.1016/j.jaci.2020.09.010 [↗](#)
240. Corse, T., et al., Clinical Outcomes of COVID-19 Patients with Pre-existing, Compromised Immune Systems: A Review of Case Reports. *Int J Med Sci*, 2020. 17(18): p. 2974-2986. doi: 10.7150/ijms.50537 [↗](#)
241. Ho, H.E., et al., Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. *J Allergy Clin Immunol Pract*, 2020. doi: 10.1016/j.jaip.2020.09.052 [↗](#)

Last Updated May 12, 2021

Content source: National Center for Immunization
and Respiratory Diseases (NCIRD), Division of Viral
Diseases